Aflibercept for the treatment of diabetic macular edema

Keegan A. Harkins, Mary Haschke, Diana V. Do

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Diabetic macular edema (DME) is an accumulation of fluid in the central retina, secondary to vascular-leakage from diabetic vascular damage. DME and other ophthalmic sequela of diabetes are the leading cause of blindness in 20 to 74-year-olds. The development of VEGF-inhibitors (anti-VEGF) has revolutionized DME treatment improving the clinician's ability to remove excess fluid from the macula, improving visual-acuity. Aflibercept is an anti-VEGF agent made of a recombinant fusion protein (consisting of VEGF receptors 1 and 2 extracellular domains) fused with the Fc-portion of human-IgG1, which binds both VEGF isoforms A and B, and placental growth factor. Phase III clinical trials and published scientific studies have demonstrated the efficacy of intravitreal aflibercept injection in the treatment of DME.

Original languageEnglish (US)
Pages (from-to)503-510
Number of pages8
JournalImmunotherapy
Volume8
Issue number5
DOIs
StatePublished - May 2016

Fingerprint

Macular Edema
Vascular Endothelial Growth Factor A
Blood Vessels
Vascular Endothelial Growth Factor B
Recombinant Fusion Proteins
Phase III Clinical Trials
Intravitreal Injections
Vascular Endothelial Growth Factor Receptor
Aptitude
Blindness
Therapeutics
Visual Acuity
Retina
Intercellular Signaling Peptides and Proteins
Protein Isoforms
Immunoglobulin G
aflibercept

Keywords

  • Aflibercept
  • anti-VEGF
  • antiangiogenesis
  • diabetic macular edema
  • diabetic retinopathy
  • placental growth factor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Harkins, K. A., Haschke, M., & Do, D. V. (2016). Aflibercept for the treatment of diabetic macular edema. Immunotherapy, 8(5), 503-510. https://doi.org/10.2217/imt.16.5

Aflibercept for the treatment of diabetic macular edema. / Harkins, Keegan A.; Haschke, Mary; Do, Diana V.

In: Immunotherapy, Vol. 8, No. 5, 05.2016, p. 503-510.

Research output: Contribution to journalArticle

Harkins, KA, Haschke, M & Do, DV 2016, 'Aflibercept for the treatment of diabetic macular edema', Immunotherapy, vol. 8, no. 5, pp. 503-510. https://doi.org/10.2217/imt.16.5
Harkins, Keegan A. ; Haschke, Mary ; Do, Diana V. / Aflibercept for the treatment of diabetic macular edema. In: Immunotherapy. 2016 ; Vol. 8, No. 5. pp. 503-510.
@article{749d4a772131461ea018dcc14ee3289f,
title = "Aflibercept for the treatment of diabetic macular edema",
abstract = "Diabetic macular edema (DME) is an accumulation of fluid in the central retina, secondary to vascular-leakage from diabetic vascular damage. DME and other ophthalmic sequela of diabetes are the leading cause of blindness in 20 to 74-year-olds. The development of VEGF-inhibitors (anti-VEGF) has revolutionized DME treatment improving the clinician's ability to remove excess fluid from the macula, improving visual-acuity. Aflibercept is an anti-VEGF agent made of a recombinant fusion protein (consisting of VEGF receptors 1 and 2 extracellular domains) fused with the Fc-portion of human-IgG1, which binds both VEGF isoforms A and B, and placental growth factor. Phase III clinical trials and published scientific studies have demonstrated the efficacy of intravitreal aflibercept injection in the treatment of DME.",
keywords = "Aflibercept, anti-VEGF, antiangiogenesis, diabetic macular edema, diabetic retinopathy, placental growth factor",
author = "Harkins, {Keegan A.} and Mary Haschke and Do, {Diana V.}",
year = "2016",
month = "5",
doi = "10.2217/imt.16.5",
language = "English (US)",
volume = "8",
pages = "503--510",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Aflibercept for the treatment of diabetic macular edema

AU - Harkins, Keegan A.

AU - Haschke, Mary

AU - Do, Diana V.

PY - 2016/5

Y1 - 2016/5

N2 - Diabetic macular edema (DME) is an accumulation of fluid in the central retina, secondary to vascular-leakage from diabetic vascular damage. DME and other ophthalmic sequela of diabetes are the leading cause of blindness in 20 to 74-year-olds. The development of VEGF-inhibitors (anti-VEGF) has revolutionized DME treatment improving the clinician's ability to remove excess fluid from the macula, improving visual-acuity. Aflibercept is an anti-VEGF agent made of a recombinant fusion protein (consisting of VEGF receptors 1 and 2 extracellular domains) fused with the Fc-portion of human-IgG1, which binds both VEGF isoforms A and B, and placental growth factor. Phase III clinical trials and published scientific studies have demonstrated the efficacy of intravitreal aflibercept injection in the treatment of DME.

AB - Diabetic macular edema (DME) is an accumulation of fluid in the central retina, secondary to vascular-leakage from diabetic vascular damage. DME and other ophthalmic sequela of diabetes are the leading cause of blindness in 20 to 74-year-olds. The development of VEGF-inhibitors (anti-VEGF) has revolutionized DME treatment improving the clinician's ability to remove excess fluid from the macula, improving visual-acuity. Aflibercept is an anti-VEGF agent made of a recombinant fusion protein (consisting of VEGF receptors 1 and 2 extracellular domains) fused with the Fc-portion of human-IgG1, which binds both VEGF isoforms A and B, and placental growth factor. Phase III clinical trials and published scientific studies have demonstrated the efficacy of intravitreal aflibercept injection in the treatment of DME.

KW - Aflibercept

KW - anti-VEGF

KW - antiangiogenesis

KW - diabetic macular edema

KW - diabetic retinopathy

KW - placental growth factor

UR - http://www.scopus.com/inward/record.url?scp=84968764294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968764294&partnerID=8YFLogxK

U2 - 10.2217/imt.16.5

DO - 10.2217/imt.16.5

M3 - Article

C2 - 26907516

AN - SCOPUS:84968764294

VL - 8

SP - 503

EP - 510

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 5

ER -